Government ❯ Health Policy ❯ FDA

Drug Approval

Antibiotics Public Statements Mifepristone Mifepristone Review Autism Treatment Leucovorin Synthetic Drugs Public Health Initiatives Guidance for Drugmakers Compassionate Use Programs

6 ARTICLES

last wk.

DEA Files to Temporarily Place 7‑OH and Related Compounds in Schedule I

The agency says the move will target concentrated and lab‑made 7‑hydroxymitragynine products because regulators link them to rising poisonings and local overdose deaths.

10 ARTICLES

4mo ago

FDA Proposes ‘Plausible Mechanism’ Pathway for Individualized Rare-Disease Therapies